Monoclonal antibodyFDA-approvedInvestigational
Sacituzumab govitecan
How it works
Delivers chemotherapy directly to cancer cells, reducing harm to healthy cells.
Cancer types
Breast Cancer— All patients
Ovarian Cancer— All patients
Efficacy
Clinical trials have shown that sacituzumab govitecan can improve overall response rate and progression-free survival in patients with platinum-resistant disease.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a New Combination Treatment for Certain Cancers | Lung Cancer | phase-1 | — | Source → |
| Sacituzumab Govitecan and Radiation Therapy Treat Choroidal Metastases in Triple Negative Breast Cancer | Breast Cancer | observational | — | Source → |
| Sacituzumab govitecan shows promise in rare breast cancer subtype | Breast Cancer | observational | The overall response rate was 36.4%, clinical benefit rate 45.5%, median progression-free survival 3.2 months and median overall survival 8.9 months. | Source → |
| Researchers Study How Cancer Drug Works in Breast Cancer Patients | Breast Cancer | phase-3 | — | Source → |
| Expert Consensus on Managing Side Effects of New Cancer Treatment | Breast Cancer | review | — | Source → |
| Gene Mutation Affects Safety of Cancer Treatment | Breast Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.